









Markets
/
Stocks
/
nasdaq-tars
/

Tarsus Pharmaceuticals Inc

TARS

66.250USD

-0.950-1.41%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

1.24BMarket Cap

LossP/E TTM



Tarsus Pharmaceuticals Inc

66.250

-0.950-1.41%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tarsus Pharmaceuticals Inc

Currency: USD Updated: 2026-03-27

Key Insights

Tarsus Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 94.62.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tarsus Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

12 / 157

Overall Ranking

57 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Tarsus Pharmaceuticals Inc Highlights

StrengthsRisks

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2487.04% year-on-year.

Undervalued

The company’s latest PE is -41.68, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 46.69M shares, decreasing 16.40% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 21.72K shares of this stock.

Analyst Rating

Based on 9 analysts

Strong Buy

Current Rating

94.625

Target Price

+49.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Tarsus Pharmaceuticals Inc is 8.29, ranking 63 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 151.67M, representing a year-over-year increase of 128.39%, while its net profit experienced a year-over-year increase of 63.77%.

Score

Industry at a Glance

Previous score

8.29

Change



Financials

8.97

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.02

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.88

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.59

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Tarsus Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Tarsus Pharmaceuticals Inc is 7.12, ranking 94 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -41.68, which is -91.90% below the recent high of -3.38 and -16.88% above the recent low of -48.71.

Score

Industry at a Glance

Previous score

7.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Tarsus Pharmaceuticals Inc is 9.11, ranking 4 out of 157 in the Pharmaceuticals industry. The average price target is 88.00, with a high of 100.00 and a low of 51.00.

Score

Industry at a Glance

Previous score

9.11

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Strong Buy

Current Rating

94.625

Target Price

+40.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Tarsus Pharmaceuticals Inc

TARS

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Tarsus Pharmaceuticals Inc is 7.15, ranking 30 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 75.80 and the support level at 59.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.27

Change

-0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.871

Sell

RSI(14)

43.861

Neutral

STOCH(KDJ)(9,3,3)

52.260

Buy

ATR(14)

3.082

Low Volatility

CCI(14)

-24.651

Neutral

Williams %R

65.377

Sell

TRIX(12,20)

-0.281

Sell

StochRSI(14)

81.934

Overbought

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

65.538

Buy

MA10

66.588

Sell

MA20

69.887

Sell

MA50

68.502

Sell

MA100

73.271

Sell

MA200

62.917

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Tarsus Pharmaceuticals Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 109.99%, representing a quarter-over-quarter decrease of 5.05%. The largest institutional shareholder is The Vanguard, holding a total of 2.39M shares, representing 5.62% of shares outstanding, with 6.35% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

3.18M

+2.11%

BlackRock Institutional Trust Company, N.A.

3.09M

-0.82%

Deep Track Capital LP

3.00M

+27.50%

Paradigm BioCapital Advisors LP

2.67M

-10.43%

The Vanguard Group, Inc.

Star Investors

2.26M

-1.10%

Jennison Associates LLC

2.60M

+5.53%

Morgan Stanley & Co. LLC

1.78M

-2.50%

Janus Henderson Investors

1.44M

-20.36%

Tang Capital Management, LLC

2.45M

Driehaus Capital Management, LLC

1.03M

+17.63%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tarsus Pharmaceuticals Inc is 7.23, ranking 40 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.